Summary & Overview
HCPCS Level II J1457: Injection, Gallium Nitrate, 1 mg
HCPCS Level II code J1457 designates a 1 mg unit of gallium nitrate for injection. This code identifies the drug product administered and is used on outpatient and clinic service lines where parenteral anticancer or specialty medications are given. Nationally, accurate reporting of medication J-codes like J1457 matters for clinical documentation, inventory tracking, and payer reimbursement consistency.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise overview of how J1457 is billed across common payers, typical sites of service, and the clinical context for use of injectable gallium nitrate.
Readers will find benchmarks and comparisons of payer coverage patterns where available, a summary of coding and billing considerations specific to HCPCS Level II drug codes, and relevant clinical context about administration settings. The piece also flags gaps where input data was not provided and points readers to sections that summarize associated billing modifiers, related codes, and service-line implications when available.
Billing Code Overview
HCPCS Level II code J1457 represents an injection of gallium nitrate, with a billing unit of 1 mg. This code is used to report administration of the specified injectable medication.
Service Type: Injectable medication administration
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or clinic setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hypercalcemia of malignancy or bone pain from metastatic cancer who requires intravenous administration of gallium nitrate for antiresorptive and antitumor effects. The oncology or infusion clinic receives an order for J1457 (injection, gallium nitrate, 1 mg) after oncologist review of laboratory studies showing elevated serum calcium or imaging confirming symptomatic bone metastases. The workflow includes verification of indication and allergies, calculation of weight-based or protocol dosing, pharmacy compounding of the injectable solution, and administration via peripheral or central IV by a registered nurse experienced in oncology infusions. Vital signs and serum chemistries are monitored before, during, and after infusion; prehydration and renal function assessment are typical because gallium compounds can affect renal function. Documentation includes indication, lot numbers, dose in milligrams, route, site, infusion start/stop times, patient tolerance, and any adverse reactions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the administration required significantly greater resources or complexity than typical (extensive monitoring, prolonged infusion time). |